Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Oregon's Honu Xpress Announces Signed Contract for Exclusive Rights to Metered-Dose Cannabis Inhaler

Honu Xpress
Posted on: 26 Apr 18

Executed Licensing and Sales Agreement would take the Mystabis-powered Dab Puff Inhaler – with up to 95% bioavailability – to the U.S. and international markets.

EUGENE, Ore., April 25, 2018 /PRNewswire/ -- Honu Xpress, Inc. (dba "Dab Puff Inhaler") (the "Company") is pleased to announce that on 4/20 the Company executed a binding Licensing and Service Agreement ("Agreement") for exclusive rights to the Mystabis inhaler technology. The rights activate after funding the transaction and meeting other customary terms.  The Mystabis Inhaler is a revolutionary patent-pending inhaler that provides pressurized metered-doses of cannabis oil directly to the lung's capillaries with little to no exhale. 

The licensing rights that Honu Xpress is purchasing include the entire world except for Canada and Australia, which were previously purchased in December 2015 by a highly-regarded large international cannabis firm with a market valuation of over $1B.

Medical Aspects. The ability to administer metered doses is something that both patients and the medical community have been waiting for eagerly. Without the use of any form of heat or combustion, this pressurized inhaler ("pMDI") delivers exact quantities of aerosolized cannabinoids in a manner that provides rapid medicinal effects while preserving the entourage effects of the cannabinoids and terpenoids, unlike distillate inhalers. 

Physicians will find the delivery mechanism to be very familiar and will appreciate the precision, controlled dosage delivery of both the THC and other licensed cannabinoid formulations (THC with THC-V, CBD, CBG, CBN, etc., to name a few promising favorites).

Mitigating the "One Too Many Hits" Problem. Mike Arnold, Honu Xpress CEO, commented, "It has been thirteen months since I discovered the inhaler technology on Google's patent search.  It's an amazing technology. It's effectively a pocket 'dab hit.'  The Dab Puff Inhaler has the potential of changing the way cannabis is consumed and overindulged.  New users will now be able to experience cannabis with a controlled and predictable dosage in a fast-acting way (estimated five- to 45-second activation time). 

"The beauty of this tech is that it is essentially an aerosolized dab hit where the non-vaporized particles are just small enough to clear the throat and enter the lungs but too big to be exhaled.  We already have meetings with potential licensees, including one publicly traded company, and find this particular device to be in high demand, given it's the only inhaler out there that uses whole-plant extract and waxes. Also, the inhaler has proof of concept already in California and Oregon under former licensing agreements.  It's an amazing discreet way to experience the potential entourage effect in a way that is totally controlled by the end user."

About Honu Xpress, Inc.

Honu Xpress, Inc., is a privately-held company based in Oregon and founded by attorney Mike Arnold.  Nothing in this press release should be construed as a solicitation for investment, as the company is not seeking capital from the public, nor is it registered by the SEC.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy securities, nor shall there be any sale of securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful. 

Amazon Author Page: http://www.amazon.com/author/mikearnold

Author of the upcoming book Weed Empire: A Trial Lawyer's Successes & Mistakes in Marijuana Startups (Cannabis Industry Secrets Book 1). Available for pre-order now on Amazon.com.

Editor's Details

Mike Wood
PharmiWeb.com
www.pharmiweb.com
editor@pharmiweb.com

Last updated on: 26/04/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.